July 2015

New Product - Javlor

Javlor (vinflunine ditartrate) binds to tubulin at or near to the vinca binding sites inhibiting its polymerisation into microtubules, which results in treadmilling suppression, disruption of microtubule dynamics, mitotic arrest and apoptotic cell death. Javlor is indicated in the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen. It is contraindicated in hypersensitivity to vinca alkaloids, recent (within 2 weeks) or current severe infection, baseline absolute neutrophil count (ANC) < 1.5 x 10⁹/L for the first administration, baseline ANC < 1.0 x 10⁹/L for subsequent administrations, platelets < 100 x 10⁹/L and also in lactation. 1 mL of Javlor contains 25 mg of vinflunine (as vinflunine ditartrate). Javlor concentrated injection is available as 50 mg/2 mL and 250 mg/10 mL vials in packs of 1’s and 10’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au